{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:09:10Z","timestamp":1790179750759,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bioorg.2020.104027","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T21:37:02Z","timestamp":1592343422000},"page":"104027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["COVID19 inhibitors: A prospective therapeutics"],"prefix":"10.1016","volume":"101","author":[{"given":"Md","family":"Jawaid Akhtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2020.104027_b0005","unstructured":"M. Cascella, M. Rajnik, A. Cuomo, S.C. Dulebohn, R.D. Napoli, Features, Evaluation and Treatment Coronavirus (COVID-19), Treasure Island (FL); StatPearls Publishing, Jan 2020, https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554776\/."},{"key":"10.1016\/j.bioorg.2020.104027_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0230802","article-title":"Detection of novel coronaviruses in bats in Myanmar","volume":"15","author":"Valitutto","year":"2020","journal-title":"Plos One"},{"key":"10.1016\/j.bioorg.2020.104027_b0015","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41423-020-0407-x","article-title":"COVID-19: a new challenge for human beings","volume":"17","author":"Yang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bioorg.2020.104027_b0020","doi-asserted-by":"crossref","unstructured":"M.F. Boni, P. Lemey, X. Jiang, T. Tsan-Yuk Lam, B. Perry, T. Castoe, A. Rambaut, D.L. Robertson, Evolutionary origins of the SARS\u2010CoV\u20102 sarbecovirus lineage responsible for the COVID-19 pandemic, bioRxiv, the preprint server for biology, 2020, pp. 1\u201325. https:\/\/doi.org\/10.1101\/2020.03.30.015008.","DOI":"10.1101\/2020.03.30.015008"},{"key":"10.1016\/j.bioorg.2020.104027_b0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2020.104027_b0030","unstructured":"Coronavirus disease (COVID-19) pandemic, World Health Organization, https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019."},{"key":"10.1016\/j.bioorg.2020.104027_b0035","unstructured":"The Viral Life Cycle, Lumen Microbiology, https:\/\/courses.lumenlearning.com\/microbiology\/chapter\/the-viral-life-cycle\/."},{"key":"10.1016\/j.bioorg.2020.104027_b0040","unstructured":"The cycle of Infection, Encyclopaedia Britannica, https:\/\/www.britannica.com\/science\/virus\/The-cycle-of-infection."},{"key":"10.1016\/j.bioorg.2020.104027_b0045","unstructured":"Viral Infection, Teach me physiology, https:\/\/teachmephysiology.com\/immune-system\/immune-responses\/viral-infection\/."},{"key":"10.1016\/j.bioorg.2020.104027_b0050","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/0929867003374886","article-title":"Discovery and development of GS 4104 (oseltamivir): An orally active influenza neuraminidase inhibitor","volume":"7","author":"Lew","year":"2000","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104027_b0055","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3201\/eid1004.030458","article-title":"Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs","volume":"10","author":"Tan","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.bioorg.2020.104027_b0060","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1128\/AAC.00339-08","article-title":"Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by plasmodium vivax","volume":"53","author":"Lim","year":"2009","journal-title":"Antimicrob. Agents. Chemother."},{"key":"10.1016\/j.bioorg.2020.104027_b0065","unstructured":"Plaquenil Hydroxychloroquine Sulfate Tablets, USP, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/009768s037s045s047lbl.pdf."},{"key":"10.1016\/j.bioorg.2020.104027_b0070","unstructured":"H. Robinson, W.H. Robinson, W. Sokolab, J. Wang, Chan, Desethylhydroxychloroquine for the treatment of diseases with inflammation. Patent JP2016518338A, 2013."},{"key":"10.1016\/j.bioorg.2020.104027_b0075","unstructured":"Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04261517."},{"key":"10.1016\/j.bioorg.2020.104027_b0080","unstructured":"Effectiveness of Hydroxychloroquine in Covid-19 Patients (Covid), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04328272."},{"key":"10.1016\/j.bioorg.2020.104027_b0085","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci."},{"key":"10.1016\/j.bioorg.2020.104027_b0090","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/dkp274","article-title":"Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells","volume":"64","author":"Smee","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bioorg.2020.104027_b0095","unstructured":"A. Ghosh, U.S. stocks inched up Thu on coordinated global stimulus and hopes of an imminent Trump 'magic drug' (Chloroquine) to treat COVID-19; Dow slips early Fri on increasing U.S.\/global lockdown, Published 20th March 2020. https:\/\/www.iforex.in\/news\/us-stocks-inched-thu-coordinated-global-stimulus-and-hopes-imminent-trump-magic-drug-chloroquine-treat-covid-19-dow-slips-early-fri-increasing-usglobal-lockdown-67589."},{"key":"10.1016\/j.bioorg.2020.104027_b0100","unstructured":"Flavipiravir, Inxight: Drugs, National center for advancing Translational sciences, https:\/\/drugs.ncats.io\/drug\/EW5GL2X7E0."},{"key":"10.1016\/j.bioorg.2020.104027_b0105","unstructured":"M. Fitzhugh, Antiviral favipiravir effective against COVID-19, China says, Published 18th March 2020, https:\/\/www.bioworld.com\/articles\/433810-antiviral-favipiravir-effective-against-covid-19-china-says."},{"key":"10.1016\/j.bioorg.2020.104027_b0110","unstructured":"Oseltamivir phosphate monograph for professionals. The American Society of Health-System Pharmacists. Archived from the original on 13 May 2016. Retrieved 8 January 2017."},{"key":"10.1016\/j.bioorg.2020.104027_b0115","unstructured":"A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04261270."},{"key":"10.1016\/j.bioorg.2020.104027_b0120","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/508439a","article-title":"Tamiflu report comes under fire","volume":"508","author":"Butler","year":"2014","journal-title":"Nat."},{"key":"10.1016\/j.bioorg.2020.104027_b0125","first-page":"ii5-10","article-title":"pharmacokinetics of Oseltaminir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations","volume":"suppl 2","author":"Davies","year":"2010","journal-title":"J. Antimicrob. Chemoth. 65"},{"key":"10.1016\/j.bioorg.2020.104027_b0130","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","article-title":"Coronavirus puts drug repurposing on the fast track","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat. Biotech."},{"key":"10.1016\/j.bioorg.2020.104027_b0135","doi-asserted-by":"crossref","unstructured":"C.O. Gualerzi, L. Brandi, A. Fabbretti, C.L. Pon, Antibiotics: Targets, Mechanisms and Resistance. 2013, Online ISBN: 9783527659685, DOI: 10.1002\/9783527659685.","DOI":"10.1002\/9783527659685"},{"key":"10.1016\/j.bioorg.2020.104027_b0140","unstructured":"M.D.B. Cao, M.D.Y. Wang, M.D.D. Wen, et al., A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19, N. Eng. J. Med. May 07, 2020, https:\/\/publons.com\/publon\/30788006\/."},{"key":"10.1016\/j.bioorg.2020.104027_b0145","first-page":"489","article-title":"Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans","volume":"25","author":"Denissen","year":"1997","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.bioorg.2020.104027_b0150","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1023\/B:PHAM.0000041457.64638.8d","article-title":"Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans","volume":"21","author":"Kumar","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioorg.2020.104027_b0155","unstructured":"Coronavirus treatments: what drugs might work against COVID-19? April 16, 2020. https:\/\/theconversation.com\/coronavirus-treatments-what-drugs-might-work-against-covid-19-135352."},{"key":"10.1016\/j.bioorg.2020.104027_b0160","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/v11040326","article-title":"Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir","volume":"11","author":"Tchesnokov","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.bioorg.2020.104027_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.onehlt.2020.100128","article-title":"Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses","volume":"9","author":"Amirian","year":"2020","journal-title":"One Health"},{"key":"10.1016\/j.bioorg.2020.104027_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2020.104027_b0175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug. Discov. Ther."},{"key":"10.1016\/j.bioorg.2020.104027_b0180","first-page":"1","article-title":"Favipiravir versus Arbidol for COVID-19: A randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.bioorg.2020.104027_b0185","first-page":"30188","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"0163","author":"Zhu","year":"2020","journal-title":"J. Inf. S"},{"key":"10.1016\/j.bioorg.2020.104027_b0190","unstructured":"A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19, https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03891420."},{"key":"10.1016\/j.bioorg.2020.104027_b0195","first-page":"e32","article-title":"Antihypertensive drugs and risk of COVID-19?","volume":"8","author":"Fang","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.bioorg.2020.104027_b0200","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016509","article-title":"Coronavirus disease 2019 (COVID-19): Do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect?","volume":"9","author":"Sommerstein","year":"2020","journal-title":"J. Am. Heart. Assoc."},{"key":"10.1016\/j.bioorg.2020.104027_b0205","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet. Resp. Med."},{"key":"10.1016\/j.bioorg.2020.104027_b0210","unstructured":"Y.L. Maxwell, ACE Inhibitors, ARBs, and COVID-19: New Insights, Advice, March 26, 2020. https:\/\/www.tctmd.com\/news\/ace-inhibitors-arbs-and-covid-19-new-insights-advice."},{"key":"10.1016\/j.bioorg.2020.104027_b0215","unstructured":"D. Rind, ACE Inhibitors and ARBs During the COVID-19 Pandemic, Clinical Spotlight, N. Eng. J. Med. April 09, 2020. https:\/\/www.jwatch.org\/na51345\/2020\/04\/09\/ace-inhibitors-and-arbs-during-covid-19-pandemic."},{"key":"10.1016\/j.bioorg.2020.104027_b0220","doi-asserted-by":"crossref","unstructured":"A.B. Patel, A. Verma, COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers:what is the evidence? JAMA 323 (2020) 1769-1770.Published online March 24th 2020. doi:10.1001\/jama.2020.4812.","DOI":"10.1001\/jama.2020.4812"},{"key":"10.1016\/j.bioorg.2020.104027_b0225","unstructured":"Cardiology societies recommend patients taking ACE inhibitors, ARBs who contract COVID-19 should continue treatment, Published March 17th 2020. https:\/\/www.healio.com\/cardiology\/vascular-medicine\/news\/online\/%7Bfe7f0842-aecb-417b-9ecf-3fe7e0ddd991%7D\/cardiology-societies-recommend-patients-taking-ace-inhibitors-arbs-who-contract-covid-19-should-continue-treatment."},{"key":"10.1016\/j.bioorg.2020.104027_b0230","unstructured":"A statement from the International Society of Hypertension on COVID-19, Published 16th march 2020. https:\/\/ish-world.com\/news\/a\/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19\/."},{"key":"10.1016\/j.bioorg.2020.104027_b0235","unstructured":"FDA approves Roche\u2019s Actemra COVID-19 trial, Published March 24th 2020. http:\/\/www.pmlive.com\/pharma_news\/fda_approves_roches_actemra_covid-19_trial_1329887."},{"key":"10.1016\/j.bioorg.2020.104027_b0240","unstructured":"Sanofi doses first patient in global Kevzara COVID-19 trial, Published March 30th 2020. https:\/\/www.pmlive.com\/pharma_news\/sanofi_doses_first_patient_in_global_kevzara_covid-19_trial_1331903."},{"key":"10.1016\/j.bioorg.2020.104027_b0245","doi-asserted-by":"crossref","unstructured":"See Sanofi Press Release, 30 March 2020, https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2020\/2020-03-30-07-00-00.","DOI":"10.5005\/ijpmr-30-4-iv"},{"key":"10.1016\/j.bioorg.2020.104027_b0250","unstructured":"Treatment of SARS Caused by COVID-19 With Ruxolitinib, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04334044."},{"key":"10.1016\/j.bioorg.2020.104027_b0255","unstructured":"Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation (RuxCoFlam), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04338958."},{"key":"10.1016\/j.bioorg.2020.104027_b0260","unstructured":"Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. (CALAVI), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04346199."},{"key":"10.1016\/j.bioorg.2020.104027_b0265","unstructured":"L. Astor, Acalabrutinib to be Tested as Treatment of Exaggerated COVID-19-Related Immune Response, https:\/\/www.targetedonc.com\/news\/acalabrutinib-to-be-tested-as-treatment-of-exaggerated-covid19related-immune-response."},{"key":"10.1016\/j.bioorg.2020.104027_b0270","unstructured":"Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (BARI-COVID), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04320277."},{"key":"10.1016\/j.bioorg.2020.104027_b0275","unstructured":"Olumiant 2 mg Film-Coated Tablets, https:\/\/www.medicines.org.uk\/emc\/product\/2434\/smpc."},{"key":"10.1016\/j.bioorg.2020.104027_b0280","doi-asserted-by":"crossref","unstructured":"P.J. Richardson, M. Corbellino, J. Stebbing, lancet. Infect. Dis. Baricitinib for COVID-19: a suitable treatment? 2020, Published Online. April 3, 2020, https:\/\/doi.org\/10.1016\/S1473-3099(20)30270-X.","DOI":"10.1016\/S1473-3099(20)30270-X"},{"issue":"4","key":"10.1016\/j.bioorg.2020.104027_b0285","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.bioorg.2020.104027_b0290","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study","volume":"117","author":"Duan","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.bioorg.2020.104027_b0295","article-title":"Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids","volume":"84","author":"Saghazadeha","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2020.104027_b0300","first-page":"10","article-title":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)","volume":"38","author":"Shanmugaraj","year":"2020","journal-title":"Asian. Pac. J. Allergy."},{"key":"10.1016\/j.bioorg.2020.104027_b0305","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.3390\/ijms21072272","article-title":"Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients?","volume":"21","author":"Jawhara","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2020.104027_b0310","doi-asserted-by":"crossref","unstructured":"B.D. Quinlan, H. Mou, L. Zhang, Y. Guo, W. He, A. Ojha, M.S. Parcells, G. Luo, W. Li, G. Zhong, H. Choe, M. Farzan, The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement, bioRxiV (2020). https:\/\/doi.org\/10.1101\/2020.04.10.036418.","DOI":"10.1101\/2020.04.10.036418"},{"key":"10.1016\/j.bioorg.2020.104027_b0315","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","article-title":"Structural basis for potent neutralization of betacoronaviruses by single-domain","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2020.104027_b0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bioorg.2020.104027_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int. J. Antimicrob. Agents."},{"key":"10.1016\/j.bioorg.2020.104027_b0330","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bjh.16727","article-title":"Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action","volume":"189","author":"Kollias","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bioorg.2020.104027_b0335","first-page":"1","article-title":"Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19","volume":"7","author":"Song","year":"2020","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.bioorg.2020.104027_b0340","doi-asserted-by":"crossref","unstructured":"Y. Kang, T. Chen, D. Mui, V. Ferrari, D. Jagasia, M. Scherrer-Crosbie, Y. Chen,Y. Han, Cardiovascular manifestations and treatment considerations in Covid-19 [published online ahead of print, 2020 Apr 30], Heart 2020; heartjnl-2020-317056. doi:10.1136\/heartjnl-2020-317056.","DOI":"10.1136\/heartjnl-2020-317056"},{"key":"10.1016\/j.bioorg.2020.104027_b0345","first-page":"1","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up","author":"Bikdeli","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bioorg.2020.104027_b0350","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost"},{"key":"10.1016\/j.bioorg.2020.104027_b0355","unstructured":"P.E. Holub, J.E. Critchfield, W.Y. Su, Amine degradation chemistry CO2 service, in; Proceedings of the Laurance Reid Gas Conditioning Conference, University of Oklahoma Foundation, 1998, pp. 146\u2013160."},{"key":"10.1016\/j.bioorg.2020.104027_b0360","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1016\/S2214-109X(20)30114-5","article-title":"Use of antiviral drugs to reduce COVID-19 transmission, Published Online","volume":"8","author":"Mitja","year":"2020","journal-title":"Lancet. Glob. Health."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820313249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820313249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:10:50Z","timestamp":1758615050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206820313249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":72,"alternative-id":["S0045206820313249"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104027","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID19 inhibitors: A prospective therapeutics","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104027"}}